Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Newron Pharmaceuticals S.p.a.

Farmitalia Carlo Erba S.p.a.

Farmitalia Carlo Erba S.r.l.

Carlo Erba S.p.a.

Piero Melloni

Patrizia Ferrari

Luigi Bernardi

Alberto Cerri

Alessandra Restivo

Giuseppe Bianchi

Emanuela Izzo

Cibele Sabido-David

Elena Colombo

Luisa Quadri

Simona Francisconi

Mauro Gobbini

Alessandro Rossi

Loredana Valentino

Marco Frigerio

Elena Folpini

Marco Santagostino

Francesco Lauria

Mara Ferrandi

Marco Torri

Arturo Della Torre

Raffaele Tommasini

Arturo D Torre

Patricia Salvati

Alberto Bonsignori

Norina Passerini

Mario Varasi

Nicoletta Almirante

Pier P Lovisolo

Sergio De Munari

Ettore Lazzari

Cibele Maria Sabido David

Maria A Cervini

Giuseppe Mazzini

Marina Mauro

Roberto Commisso

Giovanni C Carniel

Paolo Salvadori

Philippe L Dostert

Nicola Mongelli

Carla Caccia

Orietta Veneroni

Simona Sputore

Giorgio Fedrizzi

Luciano Dho

Gloria Padoani

Giuliana Salani

Monica Florio

Roberto Villa

Maria Luisa Quadri

Marcello Calabresi

Fulvio Serra

Stefania Vallese

Roberto Forlani

Stefania Nikem Vallese

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) whereinX, Y, Z, R, R, R, R, R'R, R, R, Rhave the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) 

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) wherein

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases.

&#x3b1;-Aminoamide derivatives useful as antimigraine agents, particularly for the treatment of head pain conditions such as migraine, cluster headache or other severe headache, are disclosed. The antimigraine agents of the invention are able to reduce or even stop the pain deriving from such conditions without, virtually, any side effects.

Alpha-aminoamide derivatives useful as antimigraine agents

This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NRgroup; Ris C-Calkyl, or C-Calkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C-Calkyl, hydroxyl, C-Calkoxy; R, Rare independently hydrogen, C-Calkyl, halogen, trifluoromethyl, hydroxy or C-Calkoxy; Ris hydrogen, C-Calkyl; R, Rare independently hydrogen, C-Calkyl, optionally substituted by hydroxy or phenyl; Ris hydrogen or straight or branched C-Calkyl; Het is a five to seven membered, saturated or unsaturated heteromonocyclic or an eight to ten membered, saturated or unsaturated heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said mono- or bicyclic groups being optionally substituted by C-Calkyl, halogen, hydroxyl or C-Calkoxy; and the pharmaceutically acceptable salts or prodrug thereof, that are active as sodium and/or calcium channel modulators and/or as selective MAO-B inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. 

Substituted benzylaminoalkylene heterocycles

This invention is related to novel cyclopentyl derivatives of the following general Formula (I), wherein X is methylene, oxygen, sulphur or a NRgroup; Ris a straight or branched C-Calkyl or C-Calkenylene or C-Calkynylene chain, optionally substituted with CF, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C-Calkyl, halogens, trifluoromethyl, hydroxy or C-Calkoxy groups; R, Rare independently hydrogen, a C-Calkyl chain, halogen, trifluoromethyl, hydroxy or C-Calkoxy groups; R, RR, Rare independently hydrogen or C-Calkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefor useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

Cyclopentyl derivatives

An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formu (I): where Xand X, which may be the same or different, are hydroxy, C-Calkoxy, phenoxy, halogen, or Xand X, when taken together are an oxygen atom and the resulting compound is a derivative of succinic anhydride; Y is halogen, a mesyloxy or a tosyloxy group, and subsequent treatment with water, then with a base and then with trimethylamine.

Process for preparing R-(-)carnitine from S-(-)-chlorosuccinic acid or from a derivative thereof

An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formula (I):where Xand X, which may be the same or different, are hydroxy, C&#x2013;Calkoxy, phenoxy, halogen, or Xand X, when taken together are an oxygen atom and the resulting compound is a derivative of succinic anhydride; Y is halogen, a mesyloxy or a tosyloxy group, and subsequent treatment with water, then with a base and then with trimethylamine.

Process for preparing R-(&#x2212;)-carnitin from S-(&#x2212;)-chlorosuccinic acid or from a derivative thereof

Process for preparing R-(-) -carnitine from S-(-)-chlorosuccinic acid or from a derivative thereof

New seco-D steroid derivatives, processes for their preparation and pharmaceutical compositions are provided, which are active on the cardiovascular system. The seco-D steroid derivatives have the following general formula (I): ##STR1##

Seco-d steroids active on the cardiovascular system, processes for their

Growing community of inventors

Bresso, Italy

Piero Melloni